Orbimed Advisors LLC Sells 64,400 Shares of Eli Lilly and Company $LLY

Orbimed Advisors LLC reduced its stake in Eli Lilly and Company (NYSE:LLY) by 21.4% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 236,800 shares of the company’s stock after selling 64,400 shares during the quarter. Eli Lilly and Company accounts for 4.0% of Orbimed Advisors LLC’s portfolio, making the stock its 6th largest position. Orbimed Advisors LLC’s holdings in Eli Lilly and Company were worth $217,802,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in LLY. Maryland Capital Advisors Inc. acquired a new position in shares of Eli Lilly and Company during the fourth quarter worth about $25,000. Osbon Capital Management LLC acquired a new stake in shares of Eli Lilly and Company in the fourth quarter valued at approximately $25,000. Basso Capital Management L.P. bought a new stake in shares of Eli Lilly and Company in the fourth quarter worth $30,000. Maseco LLP lifted its position in shares of Eli Lilly and Company by 466.7% in the first quarter. Maseco LLP now owns 34 shares of the company’s stock worth $31,000 after purchasing an additional 28 shares in the last quarter. Finally, E Fund Management Hong Kong Co. Ltd. boosted its holdings in Eli Lilly and Company by 342.9% during the fourth quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock worth $32,000 after purchasing an additional 24 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

Shares of LLY opened at $1,196.18 on Monday. The company has a market cap of $1.13 trillion, a PE ratio of 42.49, a price-to-earnings-growth ratio of 1.48 and a beta of 0.51. The firm has a 50-day moving average of $1,136.56 and a 200-day moving average of $1,040.14. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,249.45. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The company had revenue of $19.80 billion for the quarter, compared to analysts’ expectations of $17.82 billion. During the same period in the prior year, the firm earned $3.34 EPS. Eli Lilly and Company’s quarterly revenue was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, equities analysts forecast that Eli Lilly and Company will post 35.03 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be paid a $1.73 dividend. The ex-dividend date is Friday, August 14th. This represents a $6.92 annualized dividend and a yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is currently 24.58%.

Wall Street Analyst Weigh In

LLY has been the topic of several recent research reports. Morgan Stanley lifted their price target on shares of Eli Lilly and Company from $1,344.00 to $1,347.00 and gave the company an “overweight” rating in a research note on Wednesday, July 8th. Truist Financial raised their price objective on Eli Lilly and Company from $1,281.00 to $1,370.00 and gave the company a “buy” rating in a report on Wednesday, July 8th. Rothschild & Co Redburn lifted their target price on Eli Lilly and Company from $880.00 to $900.00 in a research report on Thursday, May 7th. Citigroup upped their target price on Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. Finally, The Goldman Sachs Group reissued a “buy” rating and set a $1,283.00 price target on shares of Eli Lilly and Company in a research report on Friday, May 22nd. Two research analysts have rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $1,283.64.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Eli Lilly reported strong late-stage results for retatrutide, its next-generation obesity drug, in two Phase 3 trials. The drug met its primary endpoint and produced substantial weight loss and A1C improvement, reinforcing expectations for a major future growth franchise. Article Title
• Positive Sentiment: The company said it now plans to file for FDA approval of retatrutide in Q1 2027, keeping the drug on a path toward commercialization and supporting the long-term growth outlook for LLY. Article Title
• Positive Sentiment: A Lilly-backed biotech, Scribe Therapeutics, priced an upsized IPO with strong demand, highlighting continued investor appetite for Lilly-associated pipeline assets and partnerships. Article Title
• Neutral Sentiment: Healthcare stocks were broadly higher late Friday, which may be lending general support to Eli Lilly’s shares. Article Title
• Negative Sentiment: Novo Nordisk is seeking a preliminary injunction to block Lilly’s weight-loss and diabetes ads, accusing the company of using outdated data and misleading comparisons versus Wegovy and Ozempic. That raises legal and regulatory risk for Eli Lilly, even if the impact is likely more headline-driven than fundamental for now. Article Title

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.